Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Clinical Safety and Immunogenicity of Two HIV Vaccines SeV-G(NP) and Ad35-GRIN in HIV-uninfected, Healthy Adult Volunteers

Go back to Resources

Clinical Safety and Immunogenicity of Two HIV Vaccines SeV-G(NP) and Ad35-GRIN in HIV-uninfected, Healthy Adult Volunteers

Authors:

Secondary:

Location:

URL:

Go back to Resources

Clindamycin Versus Trimethoprim-Sulfamethoxazole for Uncomplicated Skin Infections

Go back to Resources

Clindamycin Versus Trimethoprim-Sulfamethoxazole for Uncomplicated Skin Infections

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results From a Phase 1 Safety Trial

Go back to Resources

Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results From a Phase 1 Safety Trial

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Changes in Lens Opacities on the Age-Related Eye Disease Study Grading Scale Predict Progression to Cataract Surgery and Vision Loss: Age-Related Eye Disease Study Report No. 34

Go back to Resources

Changes in Lens Opacities on the Age-Related Eye Disease Study Grading Scale Predict Progression to Cataract Surgery and Vision Loss: Age-Related Eye Disease Study Report No. 34

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Best Method for Right Atrial Volume Assessment by Two-Dimensional Echocardiography: Validation with Magnetic Resonance Imaging

Go back to Resources

Best Method for Right Atrial Volume Assessment by Two-Dimensional Echocardiography: Validation with Magnetic Resonance Imaging

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Assessment of Viral Inhibition Activity in Low Seroprevalent Adenovirus-35 Vectored HIV Vaccines +/- Adjuvanted Protein or Electroporated DNA

Go back to Resources

Assessment of Viral Inhibition Activity in Low Seroprevalent Adenovirus-35 Vectored HIV Vaccines +/- Adjuvanted Protein or Electroporated DNA

Authors:

Secondary:

Location:

URL:

Go back to Resources

Assessment of Immature Platelet Fraction in the Diagnosis of Wiskott-Aldrich Syndrome

Go back to Resources

Assessment of Immature Platelet Fraction in the Diagnosis of Wiskott-Aldrich Syndrome

Authors:

Secondary:

Volume:

URL:

Keywords:

Abstract:

Go back to Resources

Alternative Endpoints Based on Health Outcomes in Stimulant Users Trials

Go back to Resources

Alternative Endpoints Based on Health Outcomes in Stimulant Users Trials

Authors:

Secondary:

Location:

URL:

Go back to Resources

Acute Air Pollution Exposure and Blood Pressure at Delivery Among Women With and Without Hypertension

Go back to Resources

Acute Air Pollution Exposure and Blood Pressure at Delivery Among Women With and Without Hypertension

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

A Randomized 36-Week Crossover Trial Comparing Ranibizumab and Bevacizumab for Diabetic Macular Edema

Go back to Resources

A Randomized 36-Week Crossover Trial Comparing Ranibizumab and Bevacizumab for Diabetic Macular Edema

Authors:

Secondary:

Location:

URL:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 219
  • Page 220
  • Page 221
  • Page 222
  • Current page 223
  • Page 224
  • Page 225
  • Page 226
  • Page 227
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification